[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

U Hennrich, M Eder - Pharmaceuticals, 2022‏ - mdpi.com
In March 2022,[177Lu] Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the
treatment of prostate cancer patients. Until now, the approval has been limited to patients …

Radiopharmaceutical therapy in cancer: clinical advances and challenges

G Sgouros, L Bodei, MR McDevitt… - Nature reviews Drug …, 2020‏ - nature.com
Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides: Focus Review

KA Morgan, SE Rudd, A Noor, PS Donnelly - Chemical Reviews, 2023‏ - ACS Publications
Molecular changes in malignant tissue can lead to an increase in the expression levels of
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …

[HTML][HTML] [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

U Hennrich, M Eder - Pharmaceuticals, 2021‏ - mdpi.com
For the positron emission tomography (PET) imaging of prostate cancer, radiotracers
targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical …

Current use of PSMA–PET in prostate cancer management

T Maurer, M Eiber, M Schwaiger… - Nature Reviews …, 2016‏ - nature.com
Currently, the findings of imaging procedures used for detection or staging of prostate
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …

Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer

M Benešová, M Schäfer, U Bauder-Wüst… - Journal of Nuclear …, 2015‏ - jnm.snmjournals.org
Despite many advances in the past years, the treatment of metastatic prostate cancer still
remains challenging. In recent years, prostate-specific membrane antigen (PSMA) inhibitors …

68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies

M Weineisen, M Schottelius, J Simecek… - Journal of Nuclear …, 2015‏ - jnm.snmjournals.org
On the basis of the high and consistent expression of prostate-specific membrane antigen
(PSMA) in metastatic prostate cancer (PC), the goal of this study was the development …

68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging

M Eder, M Schäfer, U Bauder-Wüst… - Bioconjugate …, 2012‏ - ACS Publications
Urea-based inhibitors of the prostate-specific membrane antigen (PSMA) represent low-
molecular-weight pepidomimetics showing the ability to image PSMA-expressing prostate …

Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging

S Sheikhbahaei, A Afshar-Oromieh, M Eiber… - European journal of …, 2017‏ - Springer
Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

The rise of PSMA ligands for diagnosis and therapy of prostate cancer

A Afshar-Oromieh, JW Babich… - Journal of Nuclear …, 2016‏ - jnm.snmjournals.org
The prostate-specific membrane antigen (PSMA) has received increased consideration
during the past few years as an excellent target for both imaging and therapy of prostate …